Dynamed Clinical Research LP

1. Moderna TX, Inc. $102,642,282 20,914 payments
2. Pfizer Inc. $29,249,171 1,529 payments
3. AbbVie, Inc. $5,295,676 1,413 payments
4. Bavarian Nordic A/S $3,847,142 464 payments
5. GlaxoSmithKline, LLC. $3,199,250 1,026 payments
6. Sun Pharmaceutical Industries Inc. $1,761,956 522 payments
7. Novavax Inc $1,595,510 141 payments
8. Emergent BioSolutions Inc. $1,446,522 1,485 payments
9. BioNTech SE $829,551 230 payments
10. Janssen Research & Development, LLC $752,867 144 payments

1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $29,918,830 563 payments
2. Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age $7,455,434 3,172 payments
3. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $6,681,458 276 payments
4. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $6,188,813 220 payments
5. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $5,968,964 364 payments
6. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $5,830,777 134 payments
7. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $5,387,711 341 payments
8. A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $4,599,923 204 payments
9. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $4,248,453 14 payments
10. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $4,102,408 2,518 payments

1. Patient care $572,375 171 payments
2. Other $484,698 34 payments
3. Professional salary support $13,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.